Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics
Purpose: We aimed to identify novel chemotherapy responsiveness biomarkers for osteosarcoma (OS) by investigating the global protein expression profile of 12 biopsy samples from OS patients. Experimental design: Six patients were classified as good responders and six as poor responders, according to...
Gespeichert in:
| Veröffentlicht in: | Proteomics. Clinical applications 2010-05, Vol.4 (5), p.560-567 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 567 |
|---|---|
| container_issue | 5 |
| container_start_page | 560 |
| container_title | Proteomics. Clinical applications |
| container_volume | 4 |
| creator | Kikuta, Kazutaka Tochigi, Naobumi Saito, Shigeru Shimoda, Tadakazu Morioka, Hideo Toyama, Yoshiaki Hosono, Ako Suehara, Yoshiyuki Beppu, Yasuo Kawai, Akira Hirohashi, Setsuo Kondo, Tadashi |
| description | Purpose: We aimed to identify novel chemotherapy responsiveness biomarkers for osteosarcoma (OS) by investigating the global protein expression profile of 12 biopsy samples from OS patients. Experimental design: Six patients were classified as good responders and six as poor responders, according to the Huvos grading system. The protein expression profiles obtained by 2‐D DIGE consisted of 2250 protein spots. Results: Among them, we identified 55 protein spots whose intensity was significantly different (Bonferroni adjusted p‐value |
| doi_str_mv | 10.1002/prca.200900172 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_816530850</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>754872768</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5102-4c56268c131013dc7c27f4d4e468ced67c15613e62d014357cfdf041107ca56f3</originalsourceid><addsrcrecordid>eNqFkc1vEzEQxS0EoqVw5Yh8QZw2jL83xxJBW1GgqkAcLceeVU1314udlOa_r6OEwK0X25r5vXnWPEJeM5gxAP5-yt7NOMAcgBn-hByzVvOmFUo-PbylPiIvSvkFoCQ38JwcccaEASOOye0V5nQfM4Z6jpRTV6ij_gaHtLrB7KYNzVimNJZ4hyOWQpcxDS7fYqbejSEGt0JalamsMBWXfe1WyR26HgNdbuiUU-0M0ZeX5Fnn-oKv9vcJ-fHp4_fFeXP57exicXrZeMWAN9IrzXXrmWDARPDGc9PJIFHWIgZtPFOaCdQ8AJNCGd-FDiRjYLxTuhMn5N1ubrX-vcayskMsHvvejZjWxbZMKwGtgkdJo2RruNFtJWc70udUSsbOTjnWPWwsA7tNwm6TsIckquDNfvR6OWA44H9XX4G3e8AV7_ouu9HH8o_jZt4atXWe77g_scfNI7b26npx-v8nmp021nTuD9oan9VGGGV_fj2ziy8fzuHzNdhWPACnLbIM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>754872768</pqid></control><display><type>article</type><title>Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Kikuta, Kazutaka ; Tochigi, Naobumi ; Saito, Shigeru ; Shimoda, Tadakazu ; Morioka, Hideo ; Toyama, Yoshiaki ; Hosono, Ako ; Suehara, Yoshiyuki ; Beppu, Yasuo ; Kawai, Akira ; Hirohashi, Setsuo ; Kondo, Tadashi</creator><creatorcontrib>Kikuta, Kazutaka ; Tochigi, Naobumi ; Saito, Shigeru ; Shimoda, Tadakazu ; Morioka, Hideo ; Toyama, Yoshiaki ; Hosono, Ako ; Suehara, Yoshiyuki ; Beppu, Yasuo ; Kawai, Akira ; Hirohashi, Setsuo ; Kondo, Tadashi</creatorcontrib><description>Purpose: We aimed to identify novel chemotherapy responsiveness biomarkers for osteosarcoma (OS) by investigating the global protein expression profile of 12 biopsy samples from OS patients. Experimental design: Six patients were classified as good responders and six as poor responders, according to the Huvos grading system. The protein expression profiles obtained by 2‐D DIGE consisted of 2250 protein spots. Results: Among them, we identified 55 protein spots whose intensity was significantly different (Bonferroni adjusted p‐value<0.01) between the two patient groups. Mass spectrometric protein identification demonstrated that the 55 spots corresponded to 38 distinct gene products including peroxiredoxin 2 (PRDX 2). Use of a specific antibody against PRDX 2 confirmed the differential expression of PRDX 2 between good and poor responders, while PRDX 2 levels as measured by Western blotting correlated highly with their corresponding 2‐D DIGE values. The predictive value of PRDX 2 expression was further confirmed by examining an additional four OS cases using Western blotting. Conclusions and clinical relevance: These results establish PRDX 2 as a candidate for chemotherapy responsiveness marker in OS. Measuring PRDX 2 in biopsy samples before treatment may contribute to more effective management of OS.</description><identifier>ISSN: 1862-8346</identifier><identifier>EISSN: 1862-8354</identifier><identifier>DOI: 10.1002/prca.200900172</identifier><identifier>PMID: 21137073</identifier><language>eng</language><publisher>Weinheim: WILEY-VCH Verlag</publisher><subject>2-D DIGE ; Adolescent ; Adult ; Biological and medical sciences ; Biomarkers, Tumor - metabolism ; Bone Neoplasms - drug therapy ; Bone Neoplasms - metabolism ; Chemotherapy ; Child ; Diseases of the osteoarticular system ; Diverse techniques ; Female ; Fundamental and applied biological sciences. Psychology ; Gene Expression Profiling ; Humans ; Male ; Medical sciences ; Molecular and cellular biology ; Osteosarcoma ; Osteosarcoma - drug therapy ; Osteosarcoma - metabolism ; Peroxiredoxin 2 ; Peroxiredoxins - metabolism ; Prognosis ; Proteomics - methods ; Tumors of striated muscle and skeleton</subject><ispartof>Proteomics. Clinical applications, 2010-05, Vol.4 (5), p.560-567</ispartof><rights>Copyright © 2010 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5102-4c56268c131013dc7c27f4d4e468ced67c15613e62d014357cfdf041107ca56f3</citedby><cites>FETCH-LOGICAL-c5102-4c56268c131013dc7c27f4d4e468ced67c15613e62d014357cfdf041107ca56f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fprca.200900172$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fprca.200900172$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22798758$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21137073$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kikuta, Kazutaka</creatorcontrib><creatorcontrib>Tochigi, Naobumi</creatorcontrib><creatorcontrib>Saito, Shigeru</creatorcontrib><creatorcontrib>Shimoda, Tadakazu</creatorcontrib><creatorcontrib>Morioka, Hideo</creatorcontrib><creatorcontrib>Toyama, Yoshiaki</creatorcontrib><creatorcontrib>Hosono, Ako</creatorcontrib><creatorcontrib>Suehara, Yoshiyuki</creatorcontrib><creatorcontrib>Beppu, Yasuo</creatorcontrib><creatorcontrib>Kawai, Akira</creatorcontrib><creatorcontrib>Hirohashi, Setsuo</creatorcontrib><creatorcontrib>Kondo, Tadashi</creatorcontrib><title>Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics</title><title>Proteomics. Clinical applications</title><addtitle>Prot. Clin. Appl</addtitle><description>Purpose: We aimed to identify novel chemotherapy responsiveness biomarkers for osteosarcoma (OS) by investigating the global protein expression profile of 12 biopsy samples from OS patients. Experimental design: Six patients were classified as good responders and six as poor responders, according to the Huvos grading system. The protein expression profiles obtained by 2‐D DIGE consisted of 2250 protein spots. Results: Among them, we identified 55 protein spots whose intensity was significantly different (Bonferroni adjusted p‐value<0.01) between the two patient groups. Mass spectrometric protein identification demonstrated that the 55 spots corresponded to 38 distinct gene products including peroxiredoxin 2 (PRDX 2). Use of a specific antibody against PRDX 2 confirmed the differential expression of PRDX 2 between good and poor responders, while PRDX 2 levels as measured by Western blotting correlated highly with their corresponding 2‐D DIGE values. The predictive value of PRDX 2 expression was further confirmed by examining an additional four OS cases using Western blotting. Conclusions and clinical relevance: These results establish PRDX 2 as a candidate for chemotherapy responsiveness marker in OS. Measuring PRDX 2 in biopsy samples before treatment may contribute to more effective management of OS.</description><subject>2-D DIGE</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Bone Neoplasms - drug therapy</subject><subject>Bone Neoplasms - metabolism</subject><subject>Chemotherapy</subject><subject>Child</subject><subject>Diseases of the osteoarticular system</subject><subject>Diverse techniques</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Gene Expression Profiling</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Molecular and cellular biology</subject><subject>Osteosarcoma</subject><subject>Osteosarcoma - drug therapy</subject><subject>Osteosarcoma - metabolism</subject><subject>Peroxiredoxin 2</subject><subject>Peroxiredoxins - metabolism</subject><subject>Prognosis</subject><subject>Proteomics - methods</subject><subject>Tumors of striated muscle and skeleton</subject><issn>1862-8346</issn><issn>1862-8354</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1vEzEQxS0EoqVw5Yh8QZw2jL83xxJBW1GgqkAcLceeVU1314udlOa_r6OEwK0X25r5vXnWPEJeM5gxAP5-yt7NOMAcgBn-hByzVvOmFUo-PbylPiIvSvkFoCQ38JwcccaEASOOye0V5nQfM4Z6jpRTV6ij_gaHtLrB7KYNzVimNJZ4hyOWQpcxDS7fYqbejSEGt0JalamsMBWXfe1WyR26HgNdbuiUU-0M0ZeX5Fnn-oKv9vcJ-fHp4_fFeXP57exicXrZeMWAN9IrzXXrmWDARPDGc9PJIFHWIgZtPFOaCdQ8AJNCGd-FDiRjYLxTuhMn5N1ubrX-vcayskMsHvvejZjWxbZMKwGtgkdJo2RruNFtJWc70udUSsbOTjnWPWwsA7tNwm6TsIckquDNfvR6OWA44H9XX4G3e8AV7_ouu9HH8o_jZt4atXWe77g_scfNI7b26npx-v8nmp021nTuD9oan9VGGGV_fj2ziy8fzuHzNdhWPACnLbIM</recordid><startdate>201005</startdate><enddate>201005</enddate><creator>Kikuta, Kazutaka</creator><creator>Tochigi, Naobumi</creator><creator>Saito, Shigeru</creator><creator>Shimoda, Tadakazu</creator><creator>Morioka, Hideo</creator><creator>Toyama, Yoshiaki</creator><creator>Hosono, Ako</creator><creator>Suehara, Yoshiyuki</creator><creator>Beppu, Yasuo</creator><creator>Kawai, Akira</creator><creator>Hirohashi, Setsuo</creator><creator>Kondo, Tadashi</creator><general>WILEY-VCH Verlag</general><general>WILEY‐VCH Verlag</general><general>Wiley</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7QP</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>201005</creationdate><title>Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics</title><author>Kikuta, Kazutaka ; Tochigi, Naobumi ; Saito, Shigeru ; Shimoda, Tadakazu ; Morioka, Hideo ; Toyama, Yoshiaki ; Hosono, Ako ; Suehara, Yoshiyuki ; Beppu, Yasuo ; Kawai, Akira ; Hirohashi, Setsuo ; Kondo, Tadashi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5102-4c56268c131013dc7c27f4d4e468ced67c15613e62d014357cfdf041107ca56f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>2-D DIGE</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Bone Neoplasms - drug therapy</topic><topic>Bone Neoplasms - metabolism</topic><topic>Chemotherapy</topic><topic>Child</topic><topic>Diseases of the osteoarticular system</topic><topic>Diverse techniques</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Gene Expression Profiling</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Molecular and cellular biology</topic><topic>Osteosarcoma</topic><topic>Osteosarcoma - drug therapy</topic><topic>Osteosarcoma - metabolism</topic><topic>Peroxiredoxin 2</topic><topic>Peroxiredoxins - metabolism</topic><topic>Prognosis</topic><topic>Proteomics - methods</topic><topic>Tumors of striated muscle and skeleton</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kikuta, Kazutaka</creatorcontrib><creatorcontrib>Tochigi, Naobumi</creatorcontrib><creatorcontrib>Saito, Shigeru</creatorcontrib><creatorcontrib>Shimoda, Tadakazu</creatorcontrib><creatorcontrib>Morioka, Hideo</creatorcontrib><creatorcontrib>Toyama, Yoshiaki</creatorcontrib><creatorcontrib>Hosono, Ako</creatorcontrib><creatorcontrib>Suehara, Yoshiyuki</creatorcontrib><creatorcontrib>Beppu, Yasuo</creatorcontrib><creatorcontrib>Kawai, Akira</creatorcontrib><creatorcontrib>Hirohashi, Setsuo</creatorcontrib><creatorcontrib>Kondo, Tadashi</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Proteomics. Clinical applications</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kikuta, Kazutaka</au><au>Tochigi, Naobumi</au><au>Saito, Shigeru</au><au>Shimoda, Tadakazu</au><au>Morioka, Hideo</au><au>Toyama, Yoshiaki</au><au>Hosono, Ako</au><au>Suehara, Yoshiyuki</au><au>Beppu, Yasuo</au><au>Kawai, Akira</au><au>Hirohashi, Setsuo</au><au>Kondo, Tadashi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics</atitle><jtitle>Proteomics. Clinical applications</jtitle><addtitle>Prot. Clin. Appl</addtitle><date>2010-05</date><risdate>2010</risdate><volume>4</volume><issue>5</issue><spage>560</spage><epage>567</epage><pages>560-567</pages><issn>1862-8346</issn><eissn>1862-8354</eissn><abstract>Purpose: We aimed to identify novel chemotherapy responsiveness biomarkers for osteosarcoma (OS) by investigating the global protein expression profile of 12 biopsy samples from OS patients. Experimental design: Six patients were classified as good responders and six as poor responders, according to the Huvos grading system. The protein expression profiles obtained by 2‐D DIGE consisted of 2250 protein spots. Results: Among them, we identified 55 protein spots whose intensity was significantly different (Bonferroni adjusted p‐value<0.01) between the two patient groups. Mass spectrometric protein identification demonstrated that the 55 spots corresponded to 38 distinct gene products including peroxiredoxin 2 (PRDX 2). Use of a specific antibody against PRDX 2 confirmed the differential expression of PRDX 2 between good and poor responders, while PRDX 2 levels as measured by Western blotting correlated highly with their corresponding 2‐D DIGE values. The predictive value of PRDX 2 expression was further confirmed by examining an additional four OS cases using Western blotting. Conclusions and clinical relevance: These results establish PRDX 2 as a candidate for chemotherapy responsiveness marker in OS. Measuring PRDX 2 in biopsy samples before treatment may contribute to more effective management of OS.</abstract><cop>Weinheim</cop><pub>WILEY-VCH Verlag</pub><pmid>21137073</pmid><doi>10.1002/prca.200900172</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1862-8346 |
| ispartof | Proteomics. Clinical applications, 2010-05, Vol.4 (5), p.560-567 |
| issn | 1862-8346 1862-8354 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_816530850 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | 2-D DIGE Adolescent Adult Biological and medical sciences Biomarkers, Tumor - metabolism Bone Neoplasms - drug therapy Bone Neoplasms - metabolism Chemotherapy Child Diseases of the osteoarticular system Diverse techniques Female Fundamental and applied biological sciences. Psychology Gene Expression Profiling Humans Male Medical sciences Molecular and cellular biology Osteosarcoma Osteosarcoma - drug therapy Osteosarcoma - metabolism Peroxiredoxin 2 Peroxiredoxins - metabolism Prognosis Proteomics - methods Tumors of striated muscle and skeleton |
| title | Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T10%3A05%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Peroxiredoxin%202%20as%20a%20chemotherapy%20responsiveness%20biomarker%20candidate%20in%20osteosarcoma%20revealed%20by%20proteomics&rft.jtitle=Proteomics.%20Clinical%20applications&rft.au=Kikuta,%20Kazutaka&rft.date=2010-05&rft.volume=4&rft.issue=5&rft.spage=560&rft.epage=567&rft.pages=560-567&rft.issn=1862-8346&rft.eissn=1862-8354&rft_id=info:doi/10.1002/prca.200900172&rft_dat=%3Cproquest_cross%3E754872768%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=754872768&rft_id=info:pmid/21137073&rfr_iscdi=true |